Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide

Bone Marrow Transplant. 2018 Aug;53(8):1044-1047. doi: 10.1038/s41409-018-0107-7. Epub 2018 Feb 1.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Cyclophosphamide / pharmacology
  • Cyclophosphamide / therapeutic use*
  • Female
  • HLA Antigens / immunology*
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunosuppressive Agents / therapeutic use*
  • Middle Aged
  • Rituximab / pharmacology
  • Rituximab / therapeutic use*
  • Tissue Donors

Substances

  • Antineoplastic Agents, Immunological
  • HLA Antigens
  • Immunosuppressive Agents
  • Rituximab
  • Cyclophosphamide